Streetbeat News

Price Targets

AFRM

BMO Capital analyst James Fotheringham has maintained a Market Perform rating on Affirm Holdings (NASDAQ:AFRM) but lowered the price target from $48 to $46.

Portfolio Pulse from Benzinga Newsdesk

May 10, 2024 | 3:15 pm

IBP

RBC Capital analyst Mike Dahl maintains a Sector Perform rating on Installed Building Products (IBP) and raises the price target from $216 to $220.

Portfolio Pulse from Benzinga Newsdesk

May 10, 2024 | 3:14 pm

VST

BMO Capital analyst James Thalacker has maintained an Outperform rating on Vistra (NYSE:VST) and increased the price target from $79 to $109.

Portfolio Pulse from Benzinga Newsdesk

May 10, 2024 | 3:13 pm

NVDA

HSBC analyst Frank Lee maintains a Buy rating on NVIDIA (NASDAQ:NVDA) and raises the price target from $1050 to $1350, indicating a positive outlook on the company's future performance.

Portfolio Pulse from Benzinga Newsdesk

May 10, 2024 | 3:12 pm

USFD

BMO Capital analyst Kelly Bania has reiterated an Outperform rating on US Foods Holding Corp. (USFD) and increased the price target from $58 to $62.

Portfolio Pulse from Benzinga Newsdesk

May 10, 2024 | 3:11 pm

SRTS

Maxim Group analyst Anthony Vendetti maintains a Buy rating on Sensus Healthcare (NASDAQ:SRTS) and raises the price target from $7 to $10.

Portfolio Pulse from Benzinga Newsdesk

May 10, 2024 | 3:09 pm

PLL

BMO Capital analyst Greg Jones has maintained a Market Perform rating on Piedmont Lithium (NASDAQ:PLL) and increased the price target from $20 to $28.

Portfolio Pulse from Benzinga Newsdesk

May 10, 2024 | 3:09 pm

NTLA

BMO Capital analyst Kostas Biliouris maintains an Outperform rating on Intellia Therapeutics (NTLA) and raises the price target from $62 to $70.

Portfolio Pulse from Benzinga Newsdesk

May 10, 2024 | 3:07 pm

RDW

Cantor Fitzgerald analyst Andres Sheppard has maintained an Overweight rating on Redwire (NYSE:RDW) and increased the price target from $5 to $6.

Portfolio Pulse from Benzinga Newsdesk

May 10, 2024 | 3:07 pm

RSSS

Maxim Group analyst Allen Klee has maintained a Buy rating on Research Solutions (NASDAQ:RSSS) and increased the price target from $5 to $6.

Portfolio Pulse from Benzinga Newsdesk

May 10, 2024 | 3:06 pm